-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the advancement of medicine, people increasingly realize that the pathophysiology of Alzheimer's disease (AD) is a highly complex and dynamic process, which begins with the early accumulation of amyloid β protein (Aβ), followed by tau deposition.
The pathophysiology of Alzheimer's disease (AD) is a highly complex and dynamic process that begins with the early accumulation of amyloid beta protein (Aβ), followed by tau deposition and neurodegeneration.
Consistent with this, plasma biomarkers have recently become a non-invasive, cost-effective, and accessible tool for assessing pathological changes that occur during AD.
Plasma Aβ42/40 levels reflect Aβ deposition and have been shown to be associated with cerebral amyloidosis in cognitively normal and cognitively impaired individuals.
In order to evaluate whether plasma biomarkers can predict changes in Aβ load, tau accumulation, brain atrophy and cognition in non-dementia individuals, in order to prevent , diagnose and develop drugs early on AD , from Karolinska Institute of Neurobiology, Sweden Academic experts have carried out relevant research, and the results have been published in the "Brain" magazine.
Preventive diagnosis
The researchers detected plasma Aβ42/40, P-tau181, P-tau217 and NfL levels in 159 non-dementia individuals, 123 AD dementia patients, and 35 non-AD dementia patients from the Swedish biofender-2 study, followed by PET Check to observe the changes of Aβ and Tau.
Plasma P-tau217 levels independently predict longitudinal tau accumulation in non-dementia individuals
Plasma P-tau217 levels independently predict longitudinal tau accumulation in non-dementia individualsPlasma Aβ42/40 levels independently predict longitudinal Aβ-PET deposition in non-dementia individuals.
Plasma Aβ42/40 levels independently predict longitudinal Aβ-PET deposition in non-dementia individuals.
The increase in longitudinal Aβ-PET was independently predicted by baseline plasma Aβ42/40 (p = 0.
Plasma P-tau217 and NfL levels independently predict the changes of longitudinal brain atrophy in non-dementia individuals.
Plasma P-tau217 and NfL levels independently predict the changes of longitudinal brain atrophy in non-dementia individuals.
Plasma P-tau217 levels independently predict cognitive decline in non-dementia individuals.
Plasma P-tau217 levels independently predict cognitive decline in non-dementia individuals.
Plasma Aβ42/40 and P-tau217 cannot predict the longitudinal changes in patients with non-AD neurodegenerative diseases.
In summary, the study shows that plasma Aβ42/40 and P-tau217 can be used as prognostic markers for the pathology of Alzheimer's disease in the future for clinical practice, research and drug development.
references:
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects, Brain, 2021;, awab163, https://doi.
Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects,
leave a message here
